Metformin for Weight Loss in Non-Diabetic Patients with Impaired Glucose Regulation

Evidence for Weight Loss Efficacy

The American Diabetes Association recommends metformin for weight loss in non-diabetic patients with prediabetes, particularly those with BMI ≥35 kg/m², age <60 years, or women with prior gestational diabetes, starting at 500 mg twice daily and titrating to 1500-2000 mg daily for optimal weight reduction 1
In randomized controlled trials, metformin achieved approximately 3% weight loss, with 25-50% of participants achieving at least 5% weight loss 2
The Diabetes Prevention Program demonstrated sustained weight loss of 6.2% at 15-year follow-up with metformin, compared to 3.7% with intensive lifestyle intervention and 2.8% with placebo 2
Doses greater than 1500 mg daily are associated with the greatest weight loss, making higher doses preferable when tolerated 2

For optimal weight loss, target doses of 1500-2000 mg daily, as higher doses demonstrate superior efficacy 2
Extended-release formulations can be used once daily to improve adherence and reduce gastrointestinal side effects 3

The American Diabetes Association specifically recommends metformin for diabetes prevention in patients with prediabetes who have BMI ≥35 kg/m², as metformin was as effective as lifestyle modification in this subgroup 1
Metformin is recommended for patients with age <60 years, as it was not significantly better than placebo in those over 60 1
Women with prior gestational diabetes mellitus are also recommended for metformin, as it resulted in a 50% reduction in diabetes risk maintained at 10-year follow-up 1

Long-term metformin use may cause biochemical vitamin B12 deficiency, and periodic measurement of vitamin B12 levels should be considered, especially in patients with anemia or peripheral neuropathy 1
Metformin should be avoided in patients with conditions causing anaerobic metabolism, significant renal impairment, liver failure, or acute heart failure 4, 5

Weight loss with metformin is sustained with continued use, as demonstrated by the 15-year Diabetes Prevention Program follow-up 2
Metformin can be used long-term for weight management in appropriate patients, unlike FDA-approved sympathomimetic agents limited to 12 weeks 2
Metformin is widely available and inexpensive compared to newer weight loss medications, making it an accessible option for patients without insurance coverage for FDA-approved obesity medications 2